从资金流向上来看，当日生物制品板块主力资金净流出2.42亿元，游资资金净流入1.78亿元，散户资金净 流入6338.2万元。生物制品板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 688331 | 荣昌生物 | -5217.72万 | 5.13% | 170.15万 | 0.17% | -5387.87万 | -5.30% | | 000534 万泽股份 | | 3663.99万 | 9.35% | -2332.45万 | -5.95% | -1331.55万 | -3.40% | | 688319 欧林生物 | | 2846.39万 | 12.93% | 395.57万 | 1.80% | -3241.96万 | -14.73% | | 688180 君实生物 | | 1294.25万 | 4.93% | 486.18万 | 1.85% | -1780.43万 | -6.79% | | 68 ...

具体来看，热景生物披露的最新前十大流通股股东数据显示，与三季度末相比，截至11月11日，汇添富 创新医药主题混合基金减持热景生物21.77万股，易方达医疗保健行业混合基金减持13.08万股。不过， 基本养老保险基金一六零二二组合持股数保持不变，香港中央结算有限公司则成为热景生物新进前十大 流通股股东。 年末往往是价值风格胜率较高的时段。有基金经理表示：时至年末，一方面处于业绩空窗期，市场缺乏 一定的确定性博弈线索；另一方面，资金流动性通常偏紧、部分资金存在避险需求，为价值风格表现稳 健的板块带来季节性增量资金，加上此时容易出现估值切换行情，低估值、盈利确定性高的价值风格或 更好 临近年底，机构忙于调仓换股。上市公司近期发布的不定期公告显示，机构减持了部分前期涨幅较多的 标的，一些细分行业龙头公司获加仓。站在当前时点，多家机构表示，看好权益资产配置价值，尤其是 价值风格投资标的，后续将深挖结构性投资机会。 机构调仓换股浮现 多家上市公司近期发布的不定期公告，让部分机构的最新调仓情况得以曝光。 类似的还有，截至11月24日，全国社保基金一一八组合、高盛公司、诺安平衡混合基金成为宠物食品龙 头公司佩蒂股份新进前十大 ...

Corporate Announcements - China Pacific Insurance announced that Vice President Yu Ze is under investigation for serious violations of discipline and law, but this will not affect the company's management [2] - Guanglian Aviation reported that its controlling shareholder and chairman Wang Zengduo has had his detention lifted, allowing him to resume his duties, with normal operations continuing [3] - China Communications Construction Company clarified that it bears no repayment or guarantee obligations related to overdue financial products linked to its controlling shareholder, and its operations remain normal [4] - Annie Co. is planning a change in control, with stock trading resuming on December 8, 2025, after a share transfer agreement is signed [5] - Guoao Technology announced that its actual controller is planning a change in control, leading to a temporary suspension of its stock [6] - ST Tianrui terminated its planned change in control due to a lack of consensus, with stock resuming trading on December 8, 2025 [7] Industry Developments - Double Star New Materials noted that leading companies in the BOPET industry have reached a consensus on production cuts to balance supply and demand, although the sustainability of long-term price increases remains uncertain [8] - First Venture received a notice of administrative penalty for failing to diligently supervise a bond project, resulting in fines and warnings, but this will not significantly impact its operations [12] - China Chemical announced that its nylon new materials project has reached full production capacity, enhancing efficiency and market competitiveness [14] Pharmaceutical Sector Updates - Hengrui Medicine reported that nine of its drugs have been included in the national medical insurance directory, with a total expected sales of approximately 8.66 billion yuan for 2024 [15] - Junshi Biosciences announced that its products have received new indications and have been included in the national medical insurance directory, enhancing market accessibility [16] - Huadong Medicine's subsidiary has had its products included in the national medical insurance and commercial insurance innovation drug directories, aiding market promotion [17] - Aidi Pharmaceutical's two innovative HIV drugs have been renewed for inclusion in the national medical insurance directory, with specific pricing established [18] - ZhiXiang JinTai's monoclonal antibody has been included in the national medical insurance directory, which is expected to positively impact future sales [19] - Fosun Pharma announced multiple products have been newly included in the national medical insurance directory, which is anticipated to positively influence future performance [20] - Zejing Pharmaceutical's drug has been included in the national medical insurance directory, which will enhance affordability and market promotion [21] - Micron Biologics' product has been included in the national medical insurance directory, with no significant impact on current performance expected [22] Shareholder Commitments - Tianci Materials' controlling shareholder has committed not to reduce his shareholding in the company for six months, reflecting confidence in the company's future [23] Major Contracts - Guangqi Technology's subsidiary signed contracts worth 696 million yuan for the mass production of metamaterials, expected to impact the company's performance in 2026 [24]

Group 1 - The company expresses an open and embracing attitude towards new technologies and closely monitors market dynamics and industry frontier technologies and applications [2]

Group 1 - The report highlights a significant divergence in the performance of various sub-sectors within the pharmaceutical industry in 2025, with the CXO and innovative drug-related sectors showing substantial growth, while the medical service sector is expected to gradually recover in 2026 due to a low base effect from 2025 [2][6][58] - The overall performance of the A-share market was positive in 2025, with the pharmaceutical and biological sector ranking 10th with a growth of 34.95%, while the CXO sector led with a growth of 58.71% [6][15] - The report emphasizes the importance of "product-driven" companies, which are expected to enter a profitability cycle as they recover from the impacts of centralized procurement and increase their R&D investments [2][29] Group 2 - The innovative drug sector is projected to continue its upward trend, with business development (BD) opportunities abroad being a key focus, indicating the global competitiveness of Chinese innovative drugs [30][34] - The medical device sector is also expected to follow a similar recovery path as innovative drugs, with increasing R&D investments and a growing number of approved innovative medical devices [43][45] - The medical service sector, despite facing short-term pressures, is anticipated to gradually recover in 2026, supported by an aging population and increasing demand for healthcare services [58] Group 3 - The report suggests specific companies to watch in various sectors, including medical devices (e.g., Sanyou Medical, Aikang Medical), innovative drugs (e.g., Innovent Biologics, Kintor Pharmaceutical), and medical services (e.g., Aier Eye Hospital, Tongce Medical) [2][29] - The report notes that the pharmaceutical sector's overall valuation remains at a historical low, with a price-to-earnings ratio of 30.82 times as of October 31, 2025, indicating potential for upward adjustment [19][20] - The report highlights the importance of key product advancements and performance realization in the innovative drug sector, particularly for products like PD-1/VEGF, which have shown promising clinical data and significant market interest [39][40]

（原标题：今日看点｜国家卫健委将就时令节气与健康（大雪）有关情况举行发布会） 12月5日重点关注的财经要闻与资本市场大事： 1、国家卫健委将就时令节气与健康（大雪）有关情况举行发布会 12月5日下午3时，国家卫健委将召开新闻发布会，介绍时令节气与健康（大雪）有关情况，并回答媒体 提问。 2、2025第二届磷锂产业高质量发展大会将举行 12月5日，11家公司共发布11个股票回购相关进展。其中，2家公司首次披露股票回购预案，1家公司回 购方案获股东大会通过，1家公司披露股票回购实施进展，7家公司回购方案已实施完毕。 从首次披露回购预案来看，当日共2家公司股票回购预案金额超千万。东阿阿胶、泛微网络回购预案金 额最高，分别拟回购不超2.0亿元、1.58亿元。从股东大会通过回购预案来看，中文传媒回购金额最高， 拟回购不超1元。 4、82.68亿元市值限售股今日解禁 12月5日，共有9家公司限售股解禁，合计解禁量为2.86亿股，按最新收盘价计算，合计解禁市值为82.68 亿元。 从解禁量来看，2家公司解禁股数超千万股。东华科技、佳驰科技、安科生物解禁量居前，解禁股数分 别为1.64亿股、1.04亿股、787.76万股。从 ...

深圳市卫光生物制品股份有限公司 第四届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 深圳市卫光生物制品股份有限公司（以下简称公司）第四届董事会第六次会议于2025年12月3日，在公 司办公楼四楼会议室以现场结合通讯的方式召开。本次会议应参加董事9名，实际参加董事9名，公司高 级管理人员列席了会议。本次会议由董事长张战先生主持，会议的召集、召开和表决程序符合《公司 法》等有关法律、法规及《公司章程》的规定。 二、董事会会议审议情况 会议经逐项审议，书面表决，审议通过了以下议案： 1.审议通过了《关于向银行申请综合授信额度的议案》; 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:002880 证券简称:卫光生物 公告编号:2025-053 董事会经审议同意公司及子公司向银行申请不超过25亿元的综合授信额度，在授权期限内，授信额度可 循环使用。本次授权自公司股东会审议通过之日起3年内有效。 具体内容详见同日刊登在指定信息披露媒体及巨潮资讯网(www.cninfo.com.cn)的《关于向银行申请综合 ...

财信证券认为，周二，A股大盘全天弱势震荡，成交量缩量，反映出当前资金追高意愿有限，市场风险 偏好仍有待提升。不过三大指数仍然处于5日均线和10日均线之上，短期修复性行情未出现趋势性变 化。因此从当日走势来看，短期大盘暂时不具备连续放量上攻的动力，或将维持震荡反弹趋势。中期来 看，随着机构资金逐步开始布局2026年方向、美联储降息靴子落地、"AI投资泡沫"担忧阶段性消退，A 股市场或将迎来新一轮做多窗口期。 中原证券认为，周二，A股市场全天震荡走低。盘中船舶制造、医药商业、消费电子以及煤炭等行业表 现较好；贵金属、能源金属、生物制品以及软件开发等行业表现较弱。经过前期的快速波动之后，上周 A股市场逐步企稳回升。中长期看，支撑本轮A股上涨的基础并未发生转变。预计上证指数围绕4000点 附近蓄势整固的可能性较大，市场风格再平衡仍将延续，周期与科技有望轮番表现。 东莞证券认为，周二，A股全天震荡调整，三大指数集体下挫。海外方面，美国供应管理协会周一公布 的数据显示，全美制造业整体景气度进一步下滑，连续第九个月跌破荣枯线。A股市场方面，当前市场 整体呈现高位震荡调整格局，资金分歧有所加大，叠加国际局势不确定性和AI板块 ...

智通财经APP讯，欧林生物(688319.SH)发布公告，公司近期配合主管税务机关的工作对公司涉税事项 进行了自查，经自查，公司本次预补缴企业所得税税款共计约420万元。截至公告披露日，公司已完成 缴纳，主管税务机关未对该事项给予处罚。目前，相关事项尚在沟通与处理过程中，最终金额需税务机 关进一步认定。 ...

人民财讯12月4日电，欧林生物(688319)12月4日公告，公司近期配合主管税务机关的工作对公司涉税事 项进行了自查。经自查，公司预补缴企业所得税税款共计420.01万元。目前公司已完成缴纳，主管税务 机关未对该事项给予处罚。相关事项尚在沟通与处理过程中，最终金额需税务机关进一步认定。若上述 金额计入公司2025年当期损益，将对公司2025年度净利润造成影响。 （原标题：欧林生物：补缴企业所得税税款420.01万元） ...